A new clinically based staging system for perihilar cholangiocarcinoma
Roongruedee Chaiteerakij1, William S Harmsen2, Carlos Romero Marrero3
11] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Mayo Clinic Cancer Center, Rochester, Minnesota, USA [2] Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
The American Journal of Gastroenterology
|November 12, 2014
Summary
A new clinical staging system for perihilar cholangiocarcinoma (pCCA) accurately predicts survival using nonoperative data. This prognostic tool aids clinicians and improves patient stratification for clinical trials, outperforming current TNM staging.
Area of Science:
- Oncology
- Hepatobiliary Surgery
- Cancer Prognostics
Background:
- Current staging systems for perihilar cholangiocarcinoma (pCCA) rely on surgical pathology, limiting their utility for unresectable cases.
- Accurate, nonoperative staging is crucial for predicting survival and stratifying patients in clinical trials for targeted therapies.
Purpose of the Study:
- To develop a novel clinical staging system for pCCA based on nonoperative diagnostic information.
- To establish a prognostic tool with relevance for all pCCA patients, including those with unresectable disease.
- To enhance patient stratification for clinical trials investigating pCCA treatments.
Main Methods:
- Retrospective analysis of clinical data from 413 pCCA patients diagnosed between 2002 and 2010.
- Development of a survival predictive model using Cox proportional hazards analysis.
- Comparison of the new staging system's performance against the AJCC/UICC 7th TNM staging system.
Main Results:
- A four-tier staging system was created incorporating ECOG status, tumor characteristics, vascular encasement, metastasis, and CA 19-9 levels.
- Median survivals for stages I-IV were 48.6, 21.8, 8.6, and 2.8 months, respectively (P<0.0001).
- The new system demonstrated superior concordance statistics (0.725) compared to the TNM system (0.614), indicating better survival prediction.
Conclusions:
- The developed clinical staging system effectively classifies pCCA patients into four distinct prognostic stages using nonoperative data.
- This system possesses strong discriminatory power and is valuable for clinical decision-making and the design of targeted therapy trials for pCCA.
